Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.
Osaka-based Takeda Pharmaceutical has exited a deal with Orexigen Therapeutics that sold back U.S. rights to obesity drug Contrave and at the same time announced a sharpened focus for its U.S. operations.
Roche is promising up to $1 billion in exchange for as many as 5 targeted cancer therapies from Blueprint Medicines, looking to bolster its own work in immuno-oncology.
Medical imaging deep learning startup Arterys has a major partnership with GE and a cardio product launch teed up as part of that for this fall. Now, it's lined up a more than $12 million Series A financing to help it transition into its next field: oncology. The San Francisco, CA-based startup had previously disclosed a smaller sum for that Series A of $7 million late last year.
Hyderabad-based Dr. Reddy's Laboratories has signed a deal with TR-Pharm to develop and manufacture three unspecified biosimilars, presumably from the India company's existing product and pipeline stable.
GlaxoSmithKline is cutting ties with Five Prime Therapeutics' in-development cancer therapy, backing out in the middle of a mesothelioma trial.
Icon has signed a deal with the International Consortium for Health Outcomes Measurement (ICHOM) to work out the best and cheapest ways of getting value-based healthcare to patients.
The Clinical Center at the National Institutes of Health (NIH) said last month that it would test a photon-counting CT scanner for the first time on humans. This is the first hospital-based research of this sort of device with more than 45 participants enrolled in the trial. The NIH noted that only three sites globally use this sort of technology.
Corvia Medical has scooped up a potential buyer with a purchase option deal, but the Massachusetts-based startup is remaining hush-hush on the identity of the strategic partner and the deal terms. The deal likely hinges on the outcome of an upcoming trial for its transcatheter InterAtrial Shunt Device to treat heart failure, or the subsequent FDA approval for which it's expected to provide the basis.
Bristol-Myers Squibb is lending its weight to a Cambridge, MA, biotech accelerator, promising to sponsor some fledging drug developers as it prepares to take up residence in an industry hotbed.